| Antiemetics: American Society of Clinical Oncology clinical practice guideline update PJ Hesketh, MG Kris, E Basch, K Bohlke, SY Barbour, RA Clark-Snow, ... Journal of Clinical Oncology 35 (28), 3240-3261, 2017 | 903* | 2017 |
| Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia SB Dusetzina, AN Winn, GA Abel, HA Huskamp, NL Keating Journal of Clinical Oncology 32 (4), 306-311, 2014 | 542 | 2014 |
| Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline E Basch, DA Loblaw, TK Oliver, M Carducci, RC Chen, JN Frame, ... Journal of Clinical Oncology 32 (30), 3436, 2014 | 301 | 2014 |
| Antiemetics: ASCO guideline update PJ Hesketh, MG Kris, E Basch, K Bohlke, SY Barbour, RA Clark-Snow, ... Journal of Clinical Oncology 38 (24), 2782-2797, 2020 | 278 | 2020 |
| Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review SB Dusetzina, AS Higashi, ER Dorsey, R Conti, HA Huskamp, S Zhu, ... Medical care 50 (6), 466-478, 2012 | 217 | 2012 |
| Background and purpose SB Dusetzina, S Tyree, AM Meyer, A Meyer, L Green, WR Carpenter Linking Data for Health Services Research: A Framework and Instructional …, 2014 | 163 | 2014 |
| Financial toxicity in adults with cancer: adverse outcomes and noncompliance TG Knight, AM Deal, SB Dusetzina, HB Muss, SK Choi, JT Bensen, ... Journal of Oncology Practice 14 (11), e665-e673, 2018 | 157 | 2018 |
| Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia AN Winn, NL Keating, SB Dusetzina Journal of Clinical Oncology 34 (36), 4323, 2016 | 127 | 2016 |
| Sorafenib effectiveness in advanced hepatocellular carcinoma HK Sanoff, YK Chang, JL Lund, BH O'Neil, SB Dusetzina The oncologist 21 (9), 1113-1120, 2016 | 125 | 2016 |
| Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000–2010 CF Garfield, ER Dorsey, S Zhu, HA Huskamp, R Conti, SB Dusetzina, ... Academic pediatrics 12 (2), 110-116, 2012 | 125 | 2012 |
| Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014 SB Dusetzina JAMA oncology 2 (7), 960-961, 2016 | 121 | 2016 |
| Financial relationships with industry among National Comprehensive Cancer Network guideline authors AP Mitchell, EM Basch, SB Dusetzina JAMA oncology 2 (12), 1628-1631, 2016 | 113 | 2016 |
| The project data sphere initiative: accelerating cancer research by sharing data AK Green, KE Reeder-Hayes, RW Corty, E Basch, MI Milowsky, ... The oncologist 20 (5), 464-e20, 2015 | 106 | 2015 |
| Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States WV Padula, RA Larson, SB Dusetzina, JF Apperley, R Hehlmann, ... Journal of the National Cancer Institute 108 (7), djw003, 2016 | 105 | 2016 |
| Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR* D BN Gaynes, SB Dusetzina, AR Ellis, RA Hansen, JF Farley, WC Miller, ... Journal of clinical psychopharmacology 32 (1), 114-119, 2012 | 103 | 2012 |
| A policy prescription for reducing health disparities—achieving pharmacoequity UR Essien, SB Dusetzina, WF Gellad Jama 326 (18), 1793-1794, 2021 | 99 | 2021 |
| Making medicines affordable: a national imperative SJ Nass, G Madhavan, NR Augustine National Academies Press, 2018 | 96 | 2018 |
| Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019 SB Dusetzina, HA Huskamp, NL Keating Jama 321 (20), 2025-2028, 2019 | 86 | 2019 |
| Trends in inpatient and outpatient hysterectomy and oophorectomy rates among commercially insured women in the United States, 2000-2014 KM Doll, SB Dusetzina, W Robinson JAMA surgery 151 (9), 876-877, 2016 | 82 | 2016 |
| Disparities in use of human epidermal growth hormone receptor 2–targeted therapy for early-stage breast cancer K Reeder-Hayes, SP Hinton, K Meng, LA Carey, SB Dusetzina Journal of Clinical Oncology 34 (17), 2003, 2016 | 73 | 2016 |
Ethan BaschUniversity of North CarolinaVerified email at med.unc.edu
